modified xingpiyiwei decoction

Modified Xingpi Yiwei Decoction is a Traditional Chinese Medicine (TCM) formulation developed and utilized by researchers at Peking University First Hospital for the management of gastric cancer, particularly as an adjuvant therapy to chemotherapy. The decoction is designed to address the TCM syndrome of Spleen-Stomach deficiency, which is frequently observed in oncology patients and correlates with impaired immune function and gastrointestinal distress. Mechanistically, the formula acts as an immunomodulator, regulating the balance of T-lymphocyte subsets (increasing the CD4+/CD8+ ratio) and modulating the production of cytokines such as Interleukin-2 (IL-2) and Tumor Necrosis Factor-alpha (TNF-α). These biological effects contribute to enhanced host anti-tumor immunity and a reduction in chemotherapy-induced toxicities, such as nausea, vomiting, and myelosuppression. The "modified" aspect of the decoction refers to the addition of specific anti-cancer or symptom-specific herbs to the core Xingpi Yiwei base, which typically includes *Astragalus membranaceus* and *Atractylodes macrocephala*.

Other names

Modified Xingpi Yiwei TangJiajian Xingpi Yiwei Decoction